Recce Ltd has released a press release.
Ethics Approval for Registrational Ph3 R327G Clinical Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- AGM Presentation
- Phase II ABSSSI Clinical Trial Advances to Final Stages
- Efficacy Data & Approval to Continue Ph II ABSSSI Trial
- Ph II ABSSSI Trial Recruitment and Dosing Passes Halfway
- Notice of Special General Meeting/Proxy Form
Later from Recce Pharmaceuticals
- AUD $6.75m R&D Rebate Approved
- Australia Patent Granted for RECCE Anti-Infectives
- Regulatory Approval for Registrational Phase 3 R327G Trial
- Patient Dosing Complete in Phase II ABSSSI Trial of R327G
- Correction to Appendix 4C and Quarterly Activities Report
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals